{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-23-028203","form_type":"8-K","ticker":"SEER","cik":"0001726445","company_name":"Seer, Inc.","filed_at":"2023-08-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:35.010502+00:00","generated_at":"2026-06-12T02:21:32.516121+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Seer Q2 revenue $4M (+11% YoY); slashes FY2023 guidance to $16-18M from $23-25M","bullets":["Net loss widened to $23.4M from $22.8M YoY; operating expenses rose 21% to $30.2M.","Product-related revenue $3.0M including $1.4M related party; service revenue $467K; grant $538K.","Cash, equivalents and investments at $396M as of June 30, 2023.","Launched Proteograph XT Assay Kit and STAC service; expanded Thermo Fisher collaboration.","Guidance cut: now expects FY2023 revenue $16-18M (prior $23-25M), 10% growth at midpoint."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-23-028203","json":"https://secwatch.observer/filing/0001628280-23-028203.json","markdown":"https://secwatch.observer/filing/0001628280-23-028203.md","text":"https://secwatch.observer/filing/0001628280-23-028203.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1726445/000162828023028203/0001628280-23-028203-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1726445/000162828023028203/seer-20230808.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-12T02:21:32.516121+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"ca3cceabc1f0f36e20d83e0a9337667d3e0f25ce","claim":"Seer, Inc. reported the second quarter ended June 30, 2023 results: revenue $4.0 million. Guidance lowered.","evidence_excerpt":"commercializing a disruptive new platform for proteomics, today reported financial results for the second quarter ended June 30, 2023. Recent Highlights • Achieved revenue of $4.0 million for the second quarter of 2023, an increase of 11% over the prior year period • Launched the Proteograph XT Assay Kit, enabling rapid proteomics across a range of sample types","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1726445/000162828023028203/0001628280-23-028203-index.htm","confidence":0.85,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the second quarter ended June 30, 2023"},{"label":"Revenue","value":"$4.0 million"},{"label":"Guidance","value":"lowered"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}